Analogues of Pyridoxal Isonicotinoyl Hydrazone (PIH) as Potential Iron Chelators for the Treatment of Neoplasia

References

• Richardson D.R., Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1997; 1331: 1–40
   PubMed Web of Science ®Google Scholar
• Ponka P., Beaumont C., Richardson D.R. Function and regulation of transferrin and ferritin. Semin. Hematol. 1998; 35(1)35–54
   PubMed Web of Science ®Google Scholar
• Klausner R.D., Ashwell G., van Renswoude J., Harford J.B., Bridges K.R. Binding of apotransferrin to K562 cells: Explanation of the transferrin cycle. Proc. Natl. Acad. Sci. USA 1983; 80: 2263–2266
   PubMed Web of Science ®Google Scholar
• Page M., Baker E., Morgan E.H. Transferrin and iron uptake by rat hepatocytes in culture. Am. J. Physiol 1984; 246: G26–G33
   PubMed Web of Science ®Google Scholar
• Trinder D., Morgan E.H., Baker E. The mechanism of iron uptake by fetal hepatocytes in culture. Hepatology 1986; 6: 852–858
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Baker E. The uptake of iron and transferrin by the human melanoma cell. Biochim. Biophys. Acta 1990; 1053: 1–12
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Baker E. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake. J. Cell. Physiol. 1994; 161: 160–168
   PubMed Web of Science ®Google Scholar
• Trinder D., Zak O., Aisen P. Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisensea inhibition of receptor expression. Hepatology 1996; 23: 1512–1520
   PubMed Web of Science ®Google Scholar
• Fleming M.D., Trenor C.C., Su M.A., Foernzler S., Beier D.R., Dietrich W.F., Andrews N.C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nature Genetics 1997; 16: 383–386
   PubMed Web of Science ®Google Scholar
• Gunshin H., Mackenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., Hediger M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482–488
   PubMed Web of Science ®Google Scholar
• Jacobs A. Low molecular weight intracellular iron transport compounds. Blood 1977; 50: 433–439
   PubMed Web of Science ®Google Scholar
• Romslo I. Intracellular transport of iron. Iron in Biochemistry and Medicine, A. Jacobs, M. Worwood. Academic, LondonUK 1980; Vol. 2: 325
   Google Scholar
• St. Pierre T., Richardson D.R., Baker E., Webb J. A low-spin iron complex in human melanoma and rat hepatoma cells and a high spin iron(H) complex in rat hepatoma cells. Biochim. Biophys. Acta 1992; 1135: 154–158
   PubMed Web of Science ®Google Scholar
• Breuer W., Epsztejn S., Cabantchik Z.I. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J. Biol. Chem. 1995; 270: 24207–24215
   Google Scholar
• Breuer W., Epsztejn S., Millgram P., Cabantchik Z.I. Transport of iron and other transition metals into cells as revealed by a fluorescent probe. Am. J. Physiol. 1995; 268: C1354–C1361
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Ponka P., Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates of iron metabolism. Blood 1996; 87: 3477–3488
   PubMed Web of Science ®Google Scholar
• Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1996; 1275: 161–203
   PubMed Web of Science ®Google Scholar
• Thelander L., Gräslund A., Thelander M. Continual presence of oxygen and iron is required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 1983; 110: 859–865
   PubMed Web of Science ®Google Scholar
• Lederman H.M., Cohen A., Lee J.W.W., Freedman M.H., Gelfand E.W. Deferoxamine: A reversible S phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748–753
   PubMed Web of Science ®Google Scholar
• Fernandez-Pol J.A. Iron: Possible cause of the G1 arrest induced in NRK cells by picolinic acid. Biochem. Biophys. Res. Commun. 1977; 78: 136–143
   PubMed Web of Science ®Google Scholar
• Brodie C., Siriwardana G., Lucas J., Schleicher R., Terada N., Szepesi A., Gelfand E., Seligman P. Neuroblastoma sensitivity to growth inhibition by deferoxamine: Evidence for a block in the G1 phase of the cell cycle. Cancer Res. 1993; 53: 3968–3975
   PubMed Web of Science ®Google Scholar
• Hileti D., Panayiotidis P., Hoffbrand A.V. Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol 1995; 89: 181–187
   PubMed Web of Science ®Google Scholar
• Ul-Haq R., Wereley J.P., Chitambar C.R. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp. Hematol 1995; 23: 428–432
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997; 89: 3025–3038
   PubMed Web of Science ®Google Scholar
• Trowbridge I.S., Omary M.B. Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc. Natl. Acad. Sci. USA 1981; 78: 3039–3043
   PubMed Web of Science ®Google Scholar
• Sutherland R., Delia D., Schneider C., Newman R., Kemshead J., Greaves M. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. USA 1981; 78: 4515–4519
   PubMed Web of Science ®Google Scholar
• Weinberg E.D. Iron withholding a defense against infection and neoplasia. Physiol. Rev. 1984; 64: 65–102
   PubMed Web of Science ®Google Scholar
• Trowbridge I.S., Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA 1982; 79: 1175–1179
   PubMed Web of Science ®Google Scholar
• Hoffbrand A.V., Ganeshaguru K., Hooton J.W.L., Tattersall M.H.N. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br. J. Haematol 1976; 33: 517–526
   PubMed Web of Science ®Google Scholar
• Blatt J., Stitely S. Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res. 1987; 47: 1749–1750
   PubMed Web of Science ®Google Scholar
• Bergeron R.J., Ingeno M.J. Microbial iron chela-tor-induced cell cycle synchronisation in L1210 cells: potential in combination chemotherapy. Cancer Res. 1987; 47: 6010–6016
   PubMed Web of Science ®Google Scholar
• Estrov Z., Tawa A., Wang X.-H., Dube I.D., Sulh H., Cohen A., Gelfand E.W., Freedman M.H. In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood 1987; 69: 757–761
   PubMed Web of Science ®Google Scholar
• Estrov Z., Cohen A., Gelfand E.W., Freedman M.H. Synergistic antiproliferative effects on HL-60 cells: Deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am. J. Pediatr. Hematol. Oncol 1988; 10: 288–291
   PubMedGoogle Scholar
• Becton D.L., Bryles P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 1988; 48: 7189–7192
   PubMed Web of Science ®Google Scholar
• Becton D.L., Roberts B. Antileukemic effects of desferoxamine on human myeloid leukemia cell lines. Cancer Res. 1989; 49: 4809–1812
   PubMed Web of Science ®Google Scholar
• Dezza L., Cazzola M., Danova M., Carlo-Stella C., Bergamaschi G., Brugnatelli S., Invernizzi R., Mazzini G., Riccardi A., Ascari E. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia 1989; 3: 104–107
   PubMed Web of Science ®Google Scholar
• Donfrancesco A., Deb G., Dominici C., Pileggi D., Castello M.A., Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990; 50: 4929–4930
   PubMed Web of Science ®Google Scholar
• Donfrancesco A., Deb G., Dominici C., Angioni A., Caniglia M., De Sio L., Fidani P., Amici A., Helson L. Deferoxamine, cyclophosphamide, etoposide, carbo-platin, and thiotepa (D-CECat): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol. 1992; 15: 319–322
   PubMed Web of Science ®Google Scholar
• Donfrancesco A., De Bernardi B., Carli M., Mancini A., Nigro M., De Sio L., Casale F., Bagnulo S., Helson L., Deb G. Deferoxamine (D) followed by Cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur. J. Cancer 1995; 31A: 612–615
   PubMed Web of Science ®Google Scholar
• Donfrancesco A., Deb G., De Sio L., Cozza R., Castellano A. Role of desferrioxamine in tumor therapy. Acta Haematol. 1996; 95: 66–69
   PubMed Web of Science ®Google Scholar
• Ponka P., Borova J., Neuwirt J., Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979; 97: 317–321
   PubMed Web of Science ®Google Scholar
• Ponka P., Borova J., Neuwirt J., Fuchs O., Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta 1979; 586: 278–297
   PubMed Web of Science ®Google Scholar
• Hoy T., Humphreys J., Jacobs A., Williams A., Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br. J. Haematol 1979; 43: 443–449
   PubMed Web of Science ®Google Scholar
• Cikrt M., Ponka P., Necas E., Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Haematol 1980; 45: 275–283
   PubMed Web of Science ®Google Scholar
• Hershko C., Avramovici-Grisaru S., Link G., Gelfand L., Sarel S. Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med. 1981; 98: 99–108
   PubMed Web of Science ®Google Scholar
• Williams A., Hoy T., Pugh A., Jacobs A. Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload. J. Pharm. Pharmacol 1982; 34: 730–732
   PubMed Web of Science ®Google Scholar
• Avramovici-Grisaru S., Sarel S., Link G., Hershko C. Synthesis of iron bis(pyridoxal isonicotinoyl hydrazone) and the in vivo iron-removal properties of some pyridoxal derivatives. J. Med. Chem. 1983; 26: 298–302
   PubMed Web of Science ®Google Scholar
• Kim B.K., Huebers H.A., Finch C.A. Effectiveness of oral iron chelators assayed in the rat. Am. J. Hematol 1987; 24: 277–284
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med. 1998, in press
   Google Scholar
• Brittenham G.M. Pyridoxal isonicotinoyl hydrazone: an effective iron chelator after oral administration. Semin. Hematol 1990; 27: 112–116
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Hefter G.T., May P.M., Webb J., Baker E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II), and zinc(II). Biol. Metals 1989; 2: 161–167
   PubMedGoogle Scholar
• Vitolo L.M.W., Hefter G.T., Clare B.W., Webb J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta 1990; 170: 171–176
   Web of Science ®Google Scholar
• Richardson D.R., Wis Vitolo L.M., Hefter G.T., May P.M., Clare B.W., Webb J., Wilairat P. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part I. Ionization characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta 1990; 170: 165–170
   Web of Science ®Google Scholar
• Edward J.T., Gauthier M., Chubb F.L., Ponka P. Synthesis of new acylhydrazones as iron-chelating compounds. J. Chem. Engin. Data 1988; 33: 538–540
   Web of Science ®Google Scholar
• Baker E., Vitolo M.L., Webb J.M. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepa-tocytes in culture. Biochem. Pharmacol 1985; 34: 3011–3017
   PubMed Web of Science ®Google Scholar
• Ponka P., Richardson D., Baker E., Schulman H.M., Edward J.T. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim. Biophys. Acta 1988; 967: 122–129
   PubMed Web of Science ®Google Scholar
• Richardson D., Baker E., Ponka P., Wilairat P., Vitolo M.L., Webb J. Effects of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture. Birth Defects 1988; 23(5B)81–88
   PubMedGoogle Scholar
• Baker E., Richardson D.R., Gross S., Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 1992; 15: 492–501
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Ponka P. The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med. 1994; 124: 660–671
   PubMed Web of Science ®Google Scholar
• Richardson D.R., Tran E., Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995; 86: 4295–4306
   PubMed Web of Science ®Google Scholar
• Huang A.R., Ponka P. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe. Biochim. Biophys. Acta 1983; 757: 306–315
   PubMed Web of Science ®Google Scholar
• Richardson D.R. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim. Biophys. Acta 1997; 1320: 45–67
   PubMed Web of Science ®Google Scholar
• Endicott J.A., Ling V. The biochemistry of p-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989; 58: 137–171
   PubMed Web of Science ®Google Scholar
• Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993; 62: 385–427
   PubMed Web of Science ®Google Scholar
• Böhme M., Büchler M., Müller M., Keppler D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 1993; 333: 193–196
   PubMed Web of Science ®Google Scholar
• Ponka P., Schulman H.M., Wilczynska A. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim. Biophys. Acta 1982; 718: 151–158
   PubMed Web of Science ®Google Scholar
• Chitambar C.R., Narasimhan J., Guy J., Sem D.S., O'Brein W.J. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res. 1991; 51: 6199–6201
   PubMed Web of Science ®Google Scholar
• Seligman P.A., Crawford E.D. Treatment of advanced transitional cell carcinoma of the bladder with continuous infusion gallium nitrate. J. Natl. Cancer Inst. 1991; 83: 1582–1584
   PubMed Web of Science ®Google Scholar
• Seligman P.A., Moran P.L., Schleicher R.B., Crawford E.D. Treatment with gallium nitrate. Evidence for interference with iron metabolism in vivo. Am. J. Hematol 1992; 41: 232–240
   PubMed Web of Science ®Google Scholar
• Johnson D.K., Murphy T.B., Rose N.J., Goodwin W.H., Pickart L. Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg. Chim. Acta 1982; 67: 159–165
   Web of Science ®Google Scholar
• Kontoghiorghes G.J., Piga A., Hoffbrand A.V. Cytotoxic effects of the lipophilic iron chelator omadine. FEBS Lett. 1986; 204: 208–212
   PubMed Web of Science ®Google Scholar
• Richardson D.R. Cytotoxic analogues of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: Effect of com-plexation with copper(II), gallium(III), and iron(III) on their anti-proliferative activity. Antimicrob. Agents Chemother. 1997; 41(9)2061–2063
   PubMed Web of Science ®Google Scholar
• Singh S., Hider R.C. Colorimetric detection of the hydroxyl radical: comparison of the hydroxyl radical generating ability of various iron complexes. Anal. Biochem. 1988; 171: 47–54
   PubMed Web of Science ®Google Scholar